Heidelberg Pharma AG
Develops cancer therapies using its proprietary ATAC Antibody-Drug Conjugate technology.
HPHA | F
Overview
Corporate Details
- ISIN(s):
- DE000A11QVV0
- LEI:
- 391200E09XYBYITR1W32
- Country:
- Germany
- Address:
- Gregor-Mendel-Str. 22, 68526 Ladenburg
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Heidelberg Pharma AG is a biopharmaceutical company specializing in the research and development of innovative cancer therapies. The company's core focus is on its proprietary Antibody-Drug Conjugate (ADC) technology platforms. A key asset is its patented ATAC® (Antibody Targeted Amanitin Conjugate) technology, which utilizes the unique biological mode of action of the toxin Amanitin. This approach aims to develop highly effective treatments for various malignant hematological and solid tumors, with the potential to overcome drug resistance and eliminate quiescent tumor cells. The company advances its own pipeline of clinical candidates while also collaborating with pharmaceutical partners.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Heidelberg Pharma AG and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-04 09:46 |
Regulatory News Service
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to…
|
English | 12.2 KB | |
| 2025-08-28 03:50 |
Regulatory News Service
Heidelberg Pharmas Partner Telix Pharmaceuticals Gives Regulatory Update for it…
|
English | 11.8 KB | |
| 2025-07-31 17:14 |
Declaration of Voting Results & Voting Rights Announcements
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
|
English | 4.5 KB | |
| 2025-07-31 00:00 |
Registration Form
Datum:31.07.2025
|
German | 9.2 KB | |
| 2025-07-31 00:00 |
Post-Annual General Meeting Information
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.12.2023 bis zum 30.11.2024
|
German | 5.9 KB | |
| 2025-07-24 14:24 |
Director's Dealing
Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, Acquisition of 90,000 shares thro…
|
English | 6.3 KB | |
| 2025-07-23 00:00 |
Related Party Transaction
Datum:23.07.2025
|
German | 8.1 KB | |
| 2025-07-10 07:03 |
Earnings Release
Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Bu…
|
English | 26.9 KB | |
| 2025-07-10 00:00 |
Interim Report
Half-yearly financial report 2024/2025
|
English | 2.1 MB | |
| 2025-05-27 08:07 |
Regulatory News Service
Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-ba…
|
English | 12.1 KB | |
| 2025-05-16 14:31 |
Post-Annual General Meeting Information
Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting…
|
English | 12.5 KB | |
| 2025-05-14 18:40 |
Regulatory News Service
Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candi…
|
English | 14.1 KB | |
| 2025-04-24 07:16 |
Quarterly Report
Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial …
|
English | 27.8 KB | |
| 2025-04-24 00:00 |
Earnings Release
Q1 statement / Q1 financial report 2024/2025
|
English | 351.9 KB | |
| 2025-04-05 15:06 |
Pre-Annual General Meeting Information
Heidelberg Pharma AG: Bekanntmachung der Einberufung zur Hauptversammlung am 15…
|
German | 123.3 KB |
Automate Your Workflow. Get a real-time feed of all Heidelberg Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Heidelberg Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-31 | Pahl, Prof. Dr. Andreas | Board | Other | None | N/A |
| 2023-12-18 | Pahl, Prof. Dr. Andreas | Board | Buy | None | 10,130.00 EUR |
| 2022-10-13 | 4H invest GmbH | Close relation | Other | None | 993,666.24 EUR |
| 2022-10-13 | Bohlini invest GmbH | Close relation | Other | None | 964,061.56 EUR |
| 2022-10-13 | MH-LT-Investments GmbH | Close relation | Other | None | 506,241.96 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 13,088.40 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 4,895.60 EUR |
| 2022-09-07 | Plate, Achim | Board | Buy | None | 30,869.92 EUR |
| 2022-09-06 | Kudlek, Dr. Birgit | Supervisory board | Other | None | 7,496.16 EUR |
| 2022-03-22 | 4H invest GmbH | Close relation | Other | None | N/A |
